Ocular Therapeutix (OCUL) Reports In-Line Q4 EPS

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.23), in-line with the analyst estimate of ($0.23). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $14.44 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Increasing unusual put volume: OCUL IRM ALOY DFTX WY CIA ATAI WGMI ROST SLS EQX CRWG MUU CAVA BURL D NBIG ZSL
• Bio-key International, Inc. (BKYI) Tops Q2 EPS by 24c